Today Pfizer’s oncology expansion got a boost with the FDA approval of biosimilar Zirabev. Good for Pfizer that the approval came shortly after its buyout of Array Pharma and good for people looking for an alternative treatment option that is reliable. There should be more of this kind coming from Pfizer considering its aggressive generic push….
There are already more of this kind with more on the way. The concern is who will be left with the relationships and experience to get access needed to promote these products? With just a few years of oncology experience, recruiters are more relentless than ever. Is it true that we can make $30k-$50k more at a biotech?
Not a clinical sell - all about pricing. And, hate to break it to you, but small startups and biotechs are not inclined to hire Pfizerbots.